Ron Do, PhD, associate professor of the Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain the importance of their recent study measuring population-based penetrance of pathogenic and loss-of-function clinical variants.
Ron Do, PhD, associate professor of the Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain the importance of their recent study, which measured penetrance of pathogenic and loss-of-function clinical variants. The study, "Population-Based Penetrance of Deleterious Clinical Variants," was published in JAMA.
Transcript
Why did you do this study?
Forrest: What really motivated us was to try to find a different way and, what some might argue, a better way to actually assess the disease risk that's associated with genetic variants. Currently, the way that we determine if a variant is so-called pathogenic—meaning it's implicated in disease—is we assign these rather broad labels of pathogenicity to them. What this means is we can call a variant pathogenic, we can call it benign, we can call it uncertain. And the problem with this is that they're very broad and coarse, and they're not very good at giving precise estimates of what the actual disease risk is. That was the major hole in the field that we want to fill, and we were able to fill this hole with a study because we had a unique resource of really large electronic health record linked biobanks with tens of thousands of people that really enabled us to assess what is the disease risk—aka the penetrance—of variants at a very, very large scale.
Why is understanding the penetrance of pathogenic and loss-of-function variants important?
Do: Penetrance is defined as the probability of disease for individuals who have the variant allele. Therefore there's value in stratifying individuals by their disease risk. Despite this value, the penetrance is actually unknown for most pathogenic variants, and for the few variants where penetrance has been reported in prior studies, they aren't necessarily accurate. Inflation of penetrance has been reported by prior studies, and these studies have used family-based or disease-focused cohorts which can cause upward bias in penetrance estimates.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More